Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Progesterone in Early Stage Endometrial Cancer
NCT04046185Phase 1Unknown
- Sponsor
- Shanghai First Maternal and Infant Health Hospital
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial of toripalimab in endometrial cancer (EC) (2 arms), sponsored by Shanghai First Maternal and Infant Health Hospital. Primary endpoints: Pathologic complete remission rate of endometrial curettage tissues at 6 months and Pathologic partial remission rate of endometrial curettage tissues at 6 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04046185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046185.